Crossing the Canyon in Prostate Cancer
Cancer drugs are hot. Sales of cancer therapies rose from $2.1 billion to $2.9 billion between 1992 and 1996, and even those figures may understate the market. Moreover, the number of cancer drugs in development has also risen dramatically. Perhaps the most fertile area of opportunity: prostate cancer, which is being boosted by an increase in consumer support, leading to faster FDA approvals, and renewed investment from Big Pharma and biotechs.
You may also be interested in...
New report shows average out-of-pocket cost per prescription of $10.67 in 2019 was unchanged from 2018. But while the number of dispensed drugs barely increased, sales jumped more than 5%.
The merger between virtual care companies Teladoc and Livongo will offer individuals a wide range of tech-enabled care during a time when telehealth continues to grow.
Regeneron's antibody cocktail for SARS-Cov-2 is largely in holding mode for now, but the company announced progress on other fronts including for Dupixent in COPD and the NGF inhibitor fasinumab.